-
Je něco špatně v tomto záznamu ?
Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor
B. Poitier, R. Chocron, C. Peronino, A. Philippe, Y. Pya, N. Rivet, U. Richez, M. Bekbossynova, N. Gendron, M. Grimmé, MC. Bories, J. Brichet, A. Capel, J. Rancic, B. Vedie, JC. Roussel, AS. Jannot, P. Jansen, A. Carpentier, P. Ivak, C....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1981 do Před 1 rokem
Freely Accessible Science Journals
od 1995
Open Access Digital Library
od 1981-01-01
Open Access Digital Library
od 1981-01-01
- MeSH
- dospělí MeSH
- hemoglobiny MeSH
- hemolýza MeSH
- lidé MeSH
- umělé srdce * škodlivé účinky MeSH
- von Willebrandova nemoc * MeSH
- von Willebrandův faktor MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Carmat bioprosthetic total artificial heart (Aeson; A-TAH) is a pulsatile and autoregulated device. The aim of this study is to evaluate level of hemolysis potential acquired von Willebrand syndrome after A-TAH implantation. METHODS: We examined the presence of hemolysis and acquired von Willebrand syndrome in adult patients receiving A-TAH support (n=10) during their whole clinical follow-up in comparison with control subjects and adult patients receiving Heartmate II or Heartmate III support. We also performed a fluid structure interaction model coupled with computational fluid dynamics simulation to evaluate the A-TAH resulting shear stress and its distribution in the blood volume. RESULTS: The cumulative duration of A-TAH support was 2087 days. A-TAH implantation did not affect plasma free hemoglobin over time, and there was no association between plasma free hemoglobin and cardiac output or beat rate. For VWF (von Willebrand factor) evaluation, A-TAH implantation did not modify multimers profile of VWF in contrast to Heartmate II and Heartmate III. Furthermore, fluid structure interaction coupled with computational fluid dynamics showed a gradually increase of blood damage according to increase of cardiac output (P<0.01), however, the blood volume fraction that endured significant shear stresses was always inferior to 0.03% of the volume for both ventricles in all regimens tested. An inverse association between cardiac output, beat rate, and high-molecular weight multimers ratio was found. CONCLUSIONS: We demonstrated that A-TAH does not cause hemolysis or AWVS. However, relationship between HMWM and cardiac output depending flow confirms relevance of VWF as a biological sensor of blood flow, even in normal range.
AP HP Biochemistry Department Georges Pompidou European Hospital France
Cardiac Surgery Department and Biosurgical Research lab
Carmat SAS Velizy Villacoublay France
National Research Cardiac Surgery Center Nur Sultan Kazakhstan
Université de Paris Cardiac Surgery Department AP HP Georges Pompidou European Hospital France
Université de Paris Innovative Therapies in Hemostasis INSERM F 75006 Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018906
- 003
- CZ-PrNML
- 005
- 20220804135157.0
- 007
- ta
- 008
- 220720s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1161/ATVBAHA.121.316833 $2 doi
- 035 __
- $a (PubMed)35139659
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Poitier, Bastien $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.) $u Cardiac Surgery Department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (B.P., A.C., C.L.) $u Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.)
- 245 10
- $a Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor / $c B. Poitier, R. Chocron, C. Peronino, A. Philippe, Y. Pya, N. Rivet, U. Richez, M. Bekbossynova, N. Gendron, M. Grimmé, MC. Bories, J. Brichet, A. Capel, J. Rancic, B. Vedie, JC. Roussel, AS. Jannot, P. Jansen, A. Carpentier, P. Ivak, C. Latremouille, I. Netuka, DM. Smadja
- 520 9_
- $a BACKGROUND: Carmat bioprosthetic total artificial heart (Aeson; A-TAH) is a pulsatile and autoregulated device. The aim of this study is to evaluate level of hemolysis potential acquired von Willebrand syndrome after A-TAH implantation. METHODS: We examined the presence of hemolysis and acquired von Willebrand syndrome in adult patients receiving A-TAH support (n=10) during their whole clinical follow-up in comparison with control subjects and adult patients receiving Heartmate II or Heartmate III support. We also performed a fluid structure interaction model coupled with computational fluid dynamics simulation to evaluate the A-TAH resulting shear stress and its distribution in the blood volume. RESULTS: The cumulative duration of A-TAH support was 2087 days. A-TAH implantation did not affect plasma free hemoglobin over time, and there was no association between plasma free hemoglobin and cardiac output or beat rate. For VWF (von Willebrand factor) evaluation, A-TAH implantation did not modify multimers profile of VWF in contrast to Heartmate II and Heartmate III. Furthermore, fluid structure interaction coupled with computational fluid dynamics showed a gradually increase of blood damage according to increase of cardiac output (P<0.01), however, the blood volume fraction that endured significant shear stresses was always inferior to 0.03% of the volume for both ventricles in all regimens tested. An inverse association between cardiac output, beat rate, and high-molecular weight multimers ratio was found. CONCLUSIONS: We demonstrated that A-TAH does not cause hemolysis or AWVS. However, relationship between HMWM and cardiac output depending flow confirms relevance of VWF as a biological sensor of blood flow, even in normal range.
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a umělé srdce $x škodlivé účinky $7 D006354
- 650 _2
- $a hemoglobiny $7 D006454
- 650 _2
- $a hemolýza $7 D006461
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a von Willebrandova nemoc $7 D014842
- 650 _2
- $a von Willebrandův faktor $7 D014841
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Chocron, Richard $u Université de Paris, PARCC, INSERM, F-75015 Paris, France, Emergency department, AP-HP, Georges Pompidou European Hospital, France (R.C.) $1 https://orcid.org/0000000254988937
- 700 1_
- $a Peronino, Christophe $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
- 700 1_
- $a Philippe, Aurélien $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
- 700 1_
- $a Pya, Yuri $u National Research Cardiac, Surgery Center, Nur-Sultan, Kazakhstan (Y.P., M.B.)
- 700 1_
- $a Rivet, Nadia $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
- 700 1_
- $a Richez, Ulysse $u Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.) $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
- 700 1_
- $a Bekbossynova, Mahabbat $u National Research Cardiac, Surgery Center, Nur-Sultan, Kazakhstan (Y.P., M.B.) $1 https://orcid.org/000000032834617X
- 700 1_
- $a Gendron, Nicolas $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.) $1 https://orcid.org/0000000348524738
- 700 1_
- $a Grimmé, Marc $u Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.) $1 https://orcid.org/0000000155254858
- 700 1_
- $a Bories, Marie Cécile $u Université de Paris, Cardiac Surgery Department, AP-HP, Georges Pompidou European Hospital, France (M.C.B.)
- 700 1_
- $a Brichet, Julie $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
- 700 1_
- $a Capel, Antoine $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.) $u Cardiac Surgery Department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (B.P., A.C., C.L.)
- 700 1_
- $a Rancic, Jeanne $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.)
- 700 1_
- $a Vedie, Benoit $u AP-HP, Biochemistry Department, Georges Pompidou European Hospital, France (B.V.) $1 https://orcid.org/0000000311675356
- 700 1_
- $a Roussel, Jean Christian $u Cardiac and thoracic Surgery Department, CHU de Nantes, hôpital Nord Laënnec, boulevard Jacques-Monod, France (J.C.R.) $1 https://orcid.org/0000000339286977
- 700 1_
- $a Jannot, Anne-Sophie $u Department of Bioinformatics, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France (A.-S.J.)
- 700 1_
- $a Jansen, Piet
- 700 1_
- $a Carpentier, Alain $u Carmat SAS, Velizy-Villacoublay, France (B.P., U.R., M.G., A.C., P.J.)
- 700 1_
- $a Ivak, Peter $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.I., I.N.)
- 700 1_
- $a Latremouille, Christian $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France (B.P., A.C., C.L.) $u Cardiac Surgery Department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (B.P., A.C., C.L.)
- 700 1_
- $a Netuka, Ivan $u Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (P.I., I.N.)
- 700 1_
- $a Smadja, David M $u Université de Paris, Innovative Therapies in Hemostasis, INSERM, F-75006 Paris, France, Hematology department and Biosurgical Research lab (Carpentier Foundation), AP-HP, Georges Pompidou European Hospital, France (C.P., A.P., N.R., U.R., N.G., J.B., J.R., D.M.S.) $1 https://orcid.org/0000000177319202
- 773 0_
- $w MED00000590 $t Arteriosclerosis, thrombosis, and vascular biology $x 1524-4636 $g Roč. 42, č. 4 (2022), s. 470-480
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35139659 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804135151 $b ABA008
- 999 __
- $a ok $b bmc $g 1822480 $s 1170149
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 42 $c 4 $d 470-480 $e 20220210 $i 1524-4636 $m Arteriosclerosis, thrombosis and vascular biology $n Arterioscler Thromb Vasc Biol $x MED00000590
- LZP __
- $a Pubmed-20220720
